In its upcoming report, Royalty Pharma (RPRX Quick QuoteRPRX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.18 per share, reflecting an increase of 0.9% compared to the same period last year. Revenues are forecasted to be $876.39 million, representing a year-over-year increase of 7.7%.

The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

That said, let's delve into the average estimates of some Royalty Pharma metrics that Wall Street analysts commonly model and monitor.

Analysts' assessment points toward 'Portfolio Receipts- Royalty Receipts- Products- Cabometyx/Cometriq' reaching $23.14 million. The estimate suggests a change of +10.2% year over year.

The consensus estimate for 'Portfolio Receipts- Royalty Receipts- Products- Tremfya' stands at $76.13 million. The estimate points to a change of +55.4% from the year-ago quarter.

Analysts forecast 'Portfolio Receipts- Royalty Receipts- Products- Trodelvy' to reach $14.61 million. The estimate points to a change of +21.7% from the year-ago quarter.

The average prediction of analysts places 'Portfolio Receipts- Royalty Receipts- Products- Other products' at $115.89 million. The estimate indicates a change of +13.6% from the prior-year quarter.

According to the collective judgment of analysts, 'Portfolio Receipts- Royalty Receipts- Products- Royalty Receipts' should come in at $873.89 million. The estimate suggests a change of +7.8% year over year.

The consensus among analysts is that 'Portfolio Receipts- Royalty Receipts- Products- Trelegy' will reach $89.87 million. The estimate indicates a change of -6.4% from the prior-year quarter.

Based on the collective assessment of analysts, 'Portfolio Receipts- Royalty Receipts- Products- Spinraza' should arrive at $13.57 million. The estimate indicates a change of -3.1% from the prior-year quarter.

Analysts predict that the 'Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise' will reach $221.60 million. The estimate indicates a year-over-year change of -0.2%.

Analysts expect 'Portfolio Receipts- Royalty Receipts- Products- Tysabri' to come in at $66.96 million. The estimate points to a change of -1.5% from the year-ago quarter.

It is projected by analysts that the 'Portfolio Receipts- Royalty Receipts- Products- Imbruvica' will reach $31.44 million. The estimate suggests a change of -23.3% year over year.

The combined assessment of analysts suggests that 'Portfolio Receipts- Royalty Receipts- Products- Xtandi' will likely reach $51.65 million. The estimate points to a change of +3.3% from the year-ago quarter.

The collective assessment of analysts points to an estimated 'Portfolio Receipts- Royalty Receipts- Products- Promacta' of $6.37 million. The estimate suggests a change of -83.2% year over year.

Over the past month, shares of Royalty Pharma have returned +14.4% versus the Zacks S&P 500 composite's +0.7% change. Currently, RPRX carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .